Comparative Pharmacology
Head-to-head clinical analysis: NEO CORT DOME versus NEO HYDELTRASOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO CORT DOME versus NEO HYDELTRASOL.
NEO-CORT-DOME vs NEO-HYDELTRASOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Hydrocortisone is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by binding to glucocorticoid receptors and modulating gene expression.
Prednisolone, a glucocorticoid, binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators, including cytokines, prostaglandins, and leukotrienes. It also inhibits phospholipase A2 and reduces immune cell activity.
Apply topically to affected area twice daily.
4-20 mg intramuscularly, intravenously, intra-articularly, or intrasynovially every 12-24 hours; maximum initial dose 40 mg.
None Documented
None Documented
2–3 hours (terminal elimination half-life of hydrocortisone); clinically, duration of action is longer due to intracellular receptor binding.
Terminal elimination half-life: 2.5–3.5 hours (adults). Note: The biologic half-life (duration of anti-inflammatory effect) is 18–36 hours due to persistence of glucocorticoid receptor-mediated effects.
Renal excretion of hydrocortisone metabolites (primarily conjugated as glucuronides and sulfates) accounts for >90% of elimination; <5% biliary/fecal.
Renal: 50–80% as unchanged drug and metabolites (primarily as glucuronide and sulfate conjugates). Fecal/biliary: minor (<10%).
Category C
Category C
Corticosteroid with Antibiotic
Corticosteroid with Antibiotic